Biogen
BIIB
$1.73 (-1.46%)
1D
1W
3M
1Y
5Y
ALL
Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company's marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; GAZYVA indicated for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS), and other anti-CD20 therapies. The Company's pipeline includes BIIB074; BAN2401; BIIB061; BIIB067, BIIB124, BIIB074, BIIB118 and TMS-007.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
Zacks Investment Research • 5 days ago • BIIB
Biogen & Partner Eisai Get EU Nod for Alzheimer's Drug LeqembiGlobeNewsWire • 6 days ago • BIIB
Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European UnionReuters • 6 days ago • BIIB
EU authorizes Eisai-Biogen's drug for treatment of early Alzheimer's diseaseZacks Investment Research • 11 days ago • BIIB
Biogen (BIIB) Soars 5.7%: Is Further Upside Left in the Stock?Seeking Alpha • 12 days ago • BIIB
Sage Therapeutics: Biogen's $7.22/Share Bid Might Say More Than The Price TagCharts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.